Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Coronavirus COVID-19 – Special Topics – Special Topics: COVID-19 Treatment and Management (G7 )

Login to access report north_east
Contact sales account_box

The treatment landscape for coronavirus disease 2019 (COVID-19) continues to evolve rapidly. Despite the availability of vaccines in the markets under study, research is ongoing to lower viral loads and improve outcomes. Although multiple therapies have been approved for COVID-19 in the markets under study—most notably Pfizer’s Paxlovid (ritonavir / nirmatrelvir), Gilead’s Veklury (remdesivir), and Merck’s molnupiravir—treatment guidelines in these countries and/or available clinical evidence do not always support their use. The high unmet need associated with preventing and treating this disease and its burden on healthcare systems worldwide presents significant opportunity for therapies in the pipeline. Indeed, numerous therapies with diverse mechanisms of action (MOAs) are in clinical development for COVID-19, and many of them are expected to launch in the next few years. The greater availability of treatment options will continue to transform the treatment landscape and help address the unmet need.

QUESTIONS ANSWERED

  • What is the treatment algorithm for COVID-19?
  • How does the treatment of COVID-19 differ based on the severity of the disease?
  • What are the key areas of unmet need and opportunity in the treatment of COVID-19?
  • What are the most promising therapies in development for COVID-19?
  • What is the expected impact of therapies in development on the treatment of COVID-19 and the market?

GEOGRAPHIES

United States, EU5, Japan

PRIMARY RESEARCH

12 KOL interviews in February to April 2023

KEY COMPANIES COVERED

Eli Lilly, Gilead, Roche, Merck, Pfizer, Regeneron

KEY DRUGS COVERED

Paxlovid (nirmatrelvir / ritonavir), Lagevrio (molnupiravir), Xevudy (sotrovimab), Veklury (remdesivir), Kineret (anakinra), Olumiant (baricitinib), REGN-COV2 (casirivimab/imdevimab), LY-CoV555 and LY-CoV016 (bamlanivimab plus etesevimab), and other Phase III assets.

PRODUCT DESCRIPTION

Special Topics reports use primary research to assess evolving trends and market effects in dynamic disease areas. Insights from this report on COVID-19 will help developers gauge the competitiveness of their late-phase pipeline candidates and design messages to support or defend their market position.

Table of contents

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east
Report
Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)
Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…
north_east
Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…
north_east
Report
Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease (US EU)
The severe to very severe chronic COPD market is crowded, with numerous LAMA, LABA/ICS, LABA/LAMA, and triple LABA/LAMA/ICS inhalers competing for use. Although dual and triple longacting…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east